ENVB — Enveric Biosciences Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $3.37
- 30-Day Move
- -38.1%
- Market Cap
- $3M
- Shares Outstanding
- 1,390,000
- P/B Ratio
- 2.29
- ROE
- -601.1%
Enveric Biosciences Inc
A read-only Alphactor snapshot forEnveric Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$3.37
30-Day Move
-38.1%
Market Cap
$3M
Shares Outstanding
1,390,000
P/B Ratio
2.29
ROE
-601.1%
$3.37
-38.1%last 90 delayed daily bars
90D High
$10.26
90D Low
$1.71
Avg Volume
2,234,898
Gross margin is running at 20.4%, which gives a quick read on operating quality before you open the full model.
Net margin is -14.1%, useful for comparing ENVB against peers in Pharmaceuticals.
ENVB is down 38.1% over the last 30 trading days shown on this page.
Latest operating income is $-2M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$3.37
30-Day Move
-38.1%
Market Cap
$3M
Shares Outstanding
1,390,000
P/B Ratio
2.29
ROE
-601.1%
ROA
-310.6%
Gross Margin
20.4%
Operating Margin
-15.9%
Net Margin
-14.1%
Debt / Equity
0
Current Ratio
1.84
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-2M
Net Income
$-2M
Gross Margin
2042.0%
Net Margin
-1405.0%
Current Ratio
1.84
Debt / Equity
0.00
Altman Z
-34.44
Distress
Piotroski
4
Moderate (4-6)
Cash Conversion
0.93x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-20M | $-19M | $-18M |
| 2023-12-31 | $0 | $-18M | $-17M | $-14M |
| 2024-12-31 | $0 | $-10M | $-10M | $-8M |
| 2025-12-31 | $0 | $-9M | $-9M | $-8M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2025-05-09
--
--
Geode Capital Management
Filed 2026-02-09
--
--
Renaissance Technologies
Filed 2025-08-13
$44,785
--
BlackRock
Filed 2024-05-10
$29,578
--
Citadel Advisors
Filed 2025-05-15
$27,883
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.